Hironobu Ihn

Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial

Dinesh Khanna, Celia J. F. Lin, Daniel E. Furst et al. · The Lancet Respiratory Medicine · 2020 · 612 citations · Full text

Autoimmune Disease, Systemic Scleroderma, Immunology +3

Characterization of SIS3, a Novel Specific Inhibitor of Smad3, and Its Effect on Transforming Growth Factor-β1-Induced Extracellular Matrix Expression

Masatoshi Jinnin, Hironobu Ihn, Kunihiko Tamaki · Molecular Pharmacology · 2005 · 441 citations

Connective Tissue Growth Factor Gene Expression in Tissue Sections From Localized Scleroderma, Keloid, and Other Fibrotic Skin Disorders

Atsuyuki Igarashi, Kiyoko Nashiro, Kanako Kikuchi et al. · Journal of Investigative Dermatology · 1996 · 436 citations · Full text

Combined Blockade of IL6 and PD-1/PD-L1 Signaling Abrogates Mutual Regulation of Their Immunosuppressive Effects in the Tumor Microenvironment

Hirotake Tsukamoto, Koji Fujieda, Azusa Miyashita et al. · Cancer Research · 2018 · 292 citations

Significant Correlation Between Connective Tissue Growth Factor Gene Expression and Skin Sclerosis in Tissue Sections from Patients with Systemic Sclerosis

Atsuyuki Igarashi, Kiyoko Nashiro, Kanako Kikuchi et al. · Journal of Investigative Dermatology · 1995 · 282 citations · Full text

Skin Sclerosis, Autoimmune Disease, Systemic Scleroderma +11